HTB

2009

PI interactions: lopinavir/rifampicin, saquinavir, atazanavir/tenofovir in pregnancy

Identification of drug interactions in clinical practice

Effect of substance abuse on ART pharmacokinetics

Effects of omeprazole on plasma levels of raltegravir

Interaction study of ketoconazole and ritonavir-boosted saquinavir

Tipranavir/ritonavir interactions with clarithromycin, fluconazole and rifabutin

Antiretroviral and statin drug-drug interactions

US Guidelines on prevention and treatment of opportunistic infections updated (2009)

BHIVA guidelines for TB/HIV coinfection (2009): online for comment

WHO global TB control report highlights that 25% of TB-related deaths occur in HIV-positive people

CD4 T-cell responses to commensal bacteria in the gut

Accelerated aging of the immune system in HIV infection

Immune recovery on antiretroviral therapy

Regulation gone awry? Elevated levels of regulatory T cells linked To disease progression

Viral resistance to a vaginal microbicide in macaques

Nations should reject UN drug policy

End of the Dr Rath affair in South Africa?

BHIVA/CHIVA Consensus Conference: Don’t Forget the Children

Hepatology: a clinical textbook

Human rights documentation and advocacy: a guide for organisations of people who use drugs

Online videos from Treatment Action Campaign, South Africa

Volume 10 Number 3/4 March/April 2009 PDF

Increased atazanavir dose recommended when used in combination with efavirenz or Atripla in naive patients

Volume 10 Number 1/2 Jan/Feb 2009

9th International Congress on Drug Therapy in HIV Infection, 9-13 November 2008, Glasgow

Summary of antiretroviral studies at Glasgow

The Antiretroviral Pregnancy Registry: individual drug safety reports on health of infants exposed to ARVs during pregnancy

Initial results from PENTA 11 trial of planned treatment interruption

Inflammation and coagulation markers askew in children with higher HIV RNA

Dosing of lopinavir/ritonavir in the CHIPS cohort

Number needed to treat to harm (NNTH) analysis of impact of underlying cardiovascular factors on risk of abacavir-related heart attack

Bone disease and HIV

Renal tubule damage with tenofovir despite normal glomerular function

10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 6-8 November 2008, London, UK

Report from the 10th IWADRLH by Jacqueline Capeau

Report from the 10th IWADRLH by Michael Dubé

Impact of body changes on the quality of life of HIV-positive treatment-experienced patients: an online community-based survey

Lost benefit of ARVs in South Africa

EMEA approves once-daily darunavir/ritonavir (800mg/100mg) for treatment-naive patients in Europe

Maraviroc safety label changes included with US traditional approval

US approval of paediatric abacavir

EMEA supports extension of D:A:D study until at least 2012 and the new remit to include non-AIDS cancers and kidney disease

Applications to approve non-refrigerated ritonavir submitted to EMEA and FDA

Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir

Serum bilirubin increases when PEG-interferon and ribavirin are used with atazanavir

Drug interactions with integrase inhibitors

Drug interactions between efavirenz and itraconazole

Effect on tacrolimus when switching from nelfinavir to fosamprenavir

Cause for caution on HIV cure report

Low-level HIV replication versus latency: identifying the source of viral rebounds during treatment interruption

Martin Delaney, leading treatment activist and founder of Project Inform, dies at 63

Report refutes HIV denialist claims on childrens HIV trials

39th Union World Conference on Lung Health

Management of hepatitis B: consensus statement and data review

PLoS medicine and PLoS clinical trials

Volume 10 Number 1/2 Jan/Feb 2009 PDF

International AIDS Conference to be held in the US after over 20-year ban

Changes at the European Medicines Agency (EMA)

Post navigation